Santhera Gains Orphan & Fast‑Track Status for AGAMREE, Targeting DMD in South Korea
Santhera’s AGAMREE earns orphan drug and fast‑track status in South Korea, offering a potential first‑in‑market DMD therapy and faster approval for patients.
- SANTHERA PHARMACEUTICALS-REG
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read